<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01884623</url>
  </required_header>
  <id_info>
    <org_study_id>2012-004967-38</org_study_id>
    <secondary_id>2012/1937</secondary_id>
    <nct_id>NCT01884623</nct_id>
  </id_info>
  <brief_title>Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer</brief_title>
  <acronym>ELAN-UNFIT</acronym>
  <official_title>Multicentric Randomized Phase III Trial Comparing Methotrexate and Cetuximab in First-line Treatment of Recurrent and/or Metastatic Squamous Cell Head and Neck Cancer in Elderly Unfit Patients According to Geriatric Evaluation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gustave Roussy, Cancer Campus, Grand Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Cancer Institute, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Ligue contre le cancer, France</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Merck Serono International SA</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Gustave Roussy, Cancer Campus, Grand Paris</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To test whether cetuximab improves efficacy/tolerance as compared to methotrexate in first
      line treatment of unfit patients ³ 70 years old with recurrent and /or metastatic HNSCC.
      Efficacy assessed by failure free survival
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>June 2013</start_date>
  <completion_date type="Anticipated">June 2019</completion_date>
  <primary_completion_date type="Anticipated">June 2017</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure free survival (FFS)</measure>
    <time_frame>From randomization to the first event among progression, treatment stop, whatever the cause, loss of 2 points or more in ADL scale and death assessed up to 16 months</time_frame>
    <description>Composite criteria of efficacy and tolerance: Failure free survival (FFS) defined as time from randomization to the first event among progression (defined by RECIST criteria), treatment stop (whatever the cause), loss of 2 points or more in Activities in Daily Living (ADL) scale and death (whatever the cause). Patients who don't have any of these events are censored at the date of last follow-up.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>From randomization to death from any cause assessed up to 1 months</time_frame>
    <description>Patients with disease progression will be treated off protocol but will be followed for overall survival evaluation.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS)</measure>
    <time_frame>From randomization to progression assessed up to 16 months</time_frame>
    <description>minimum time from randomization to progression as defined by RECIST criteria or to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Head Neck Cancer Squamous Cell Recurrent</condition>
  <arm_group>
    <arm_group_label>Cetuximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Dosing schedule: 500 mg/m², every two weeks (q2w) Mode of administration: IV</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Methotrexate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dosing schedule: 40mg/m2 weekly (q1w) Mode of administration: IV</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Cetuximab</intervention_name>
    <arm_group_label>Cetuximab</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methotrexate</intervention_name>
    <arm_group_label>Methotrexate</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 70 or over

          -  Included in ELAN-ONCOVAL study and considered as &quot;Unfit&quot; by geriatric evaluation done
             in this study

          -  PS &lt; 3

          -  Histologically confirmed diagnosis of squamous cell carcinoma of head and neck: oral
             cavity, oropharynx, hypopharynx, larynx.

          -  Recurrence and/or metastatic disease not suitable for local therapy.

          -  At least one measurable lesion (RECIST 1.1) by CT or MRI.

          -  No brain metastasis.

          -  Clearance of creatinine &gt;= 50ml/mn (MDRD).

          -  Adequate haematological functions defined as follows: absolute neutrophil count &gt; 1.5
             x 109/l, platelet &gt; 100 x 109/l, hemoglobin &gt;= 9.5 g/dl

          -  Adequate hepatic functions with serum total bilirubin &lt;1.25 Upper limit of normal
             range (ULN); SGOT/SGPT &lt; 5 ULN; AP &lt; 5 ULN

          -  Life expectancy &gt; 12 weeks.

          -  Males of reproductive potential must agree to use an effective contraceptive method
             during the treatment and after the end of treatment during five months.

          -  Signed informed consent.

          -  Affiliated to Health Insurance regimen (according to Public Health Law of August 9,
             2004).

        Exclusion Criteria:

          -  Included in ELAN-ONCOVAL study and considered as &quot;Fit&quot; by geriatric evaluation

          -  Patients with nasopharyngeal cancer, paranasal sinus, or cervical lymph nodes
             metastasis of unknown origin.

          -  Prior systemic chemotherapy for the squamous cell carcinoma of head and neck, except
             if given as part of a multimodal treatment for locally advanced disease which was
             completed more than 6 months prior to study entry.

          -  Prior anti-EGFR therapy, except if given in association with radiotherapy for squamous
             cell carcinoma of head and neck which was completed more than 12 months prior to study
             entry.

          -  Surgery (excluding prior diagnostic biopsy) or irradiation within 4 weeks before study
             entry.

          -  Brain metastasis

          -  Active infection including tuberculosis and HIV infection.

          -  Severe or uncontrolled cardiovascular disease (congestive heart failure NYHA III or
             IV), unstable angina pectoris, history of myocardial infarction within the last twelve
             months, significant arrhythmias

          -  Concomitant immunotherapy or antitumoral hormonotherapy.

          -  Requirement for treatment with any of the prohibited concomitant medications listed in
             SPC of Cetuximab and Methotrexate. In particular, acetylsalicylic acid used at
             analgesic, antipyretic or anti-inflammatory doses (see Section 6.3.2).

          -  Malignancies within 5 years prior to randomization, with the exception of adequately
             treated basal or squamous cell skin cancer and carcinoma in situ of the cervix

          -  Known allergic hypersensitivity to cetuximab or known positive results of tests for
             IgE antibodies against cetuximab (α-1-3-galactose) and/or methotrexate or any of their
             excipients.

          -  Other severe acute or chronic psychiatric or medical condition, or significant
             laboratory abnormality requiring further investigation that may cause undue risk for
             the patient's safety, inhibit protocol participation, or interfere with interpretation
             of study results, and in the judgment of the investigator would make the patient
             inappropriate for entry into this study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>70 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Joel GUIGAY, Pr</last_name>
    <role>Study Chair</role>
    <affiliation>Gustave Roussy, Cancer Campus, Grand Paris</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Joel GUIGAY, Pr</last_name>
    <phone>0142116536</phone>
    <phone_ext>+33</phone_ext>
    <email>joel.guigay@gustaveroussy.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Anne AUPERIN, MD</last_name>
    <phone>0142445499</phone>
    <phone_ext>+33</phone_ext>
    <email>anne.auerin@gustaveroussy.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Institut Gustave Roussy</name>
      <address>
        <city>Villejuif</city>
        <state>Val de Marne</state>
        <zip>94805</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joël GUIGAY, Pr</last_name>
      <phone>0142116536</phone>
      <phone_ext>+33</phone_ext>
      <email>joel.guigay@gustaveroussy.fr</email>
    </contact>
    <contact_backup>
      <last_name>Anne AUPERIN, MD</last_name>
      <phone>0142115499</phone>
      <phone_ext>+33</phone_ext>
      <email>anne.auperin@gustaveroussy.fr</email>
    </contact_backup>
    <investigator>
      <last_name>Joel GUIGAY, Pr</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>June 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>June 18, 2013</study_first_submitted>
  <study_first_submitted_qc>June 20, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 24, 2013</study_first_posted>
  <last_update_submitted>June 8, 2016</last_update_submitted>
  <last_update_submitted_qc>June 8, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 9, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methotrexate</mesh_term>
    <mesh_term>Cetuximab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

